PF-Atlas › Clinical Trials › NCT06181370
Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF
AGMB-447 · Phase 1
Registry ID
NCT06181370
Phase
Phase 1
Status
Completed
Drug / intervention
AGMB-447
Sponsor
Agomab Spain S.L.
Start
2023-12-01
Enrollment
143
Locations
1
About this trial
The purpose of this study is to measure the safety, tolerability PK and PD of inhaled AGMB-477 compared with placebo in healthy participants and participants with IPF. This is an integrated phase 1, single center, 3-part, double-blind, randomized, placebo-controlled SAD (Part A) and MAD (Part B) study in healthy participants and multiple dose study in IPF participants (Part C). Safety, tolerability PK and PD will be assessed following single ascending, multiple ascending and multiple dosing of AGMB-447 administered via nebulizer in Part A, B and C, respectively.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06181370 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.